Leap Therapeutics is a clinical-stage biopharmaceutical company acquiring and developing novel therapeutics at the leading edge of cancer research.
March 14, 2018Leap Therapeutics Provides DKN-01 Program Update and Announces Scientific Presentations at AACR Annual Meeting
March 07, 2018Leap Therapeutics to Present at 2018 Barclays Global Healthcare Conference
February 23, 2018Leap Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Announces Date of its Annual Meeting of Stockholders
February 06, 2018Leap Therapeutics to Present at the 20th Annual BIO CEO & Investor Conference
January 16, 2018Leap Therapeutics Announces First Patient Dosed with TRX518 Combination Therapy in Advanced Solid Tumors Trial
as of 4:00 PM ETMar 16, 2018
Data provided by Nasdaq. Minimum 15 minutes delayed.